Lung cancer

Global Ultrasonic Electrosurgical Devices (Consumables, Generators) Market Analysis & Forecasts, 2017-2020 & 2021-2028 - ResearchAndMarkets.com

Biotechnology, Health, Surgery, Medical Devices, Degenerative disease, Chapter Three, Cancer, Adoption, Prostate cancer, Consumables, Agency for Healthcare Research and Quality, Lung cancer, Diabetes, Death, Neoplasm, CAGR, Toxicity, Prevalence, USD, Agency, AHRQ, Application, Cardiology, Breast cancer, HIFU, Incidence, Conditional sentence, Laparoscopy, Globe, Medical device, Pet, Medical imaging
Tuesday, November 30, 2021 - 4:25pm

The global ultrasonic electrosurgical devices market size is expected to reach USD 5.45 billion by 2028 and is expected to expand at a CAGR of 5.04% from 2021 to 2028.

Key Points: 
  • The global ultrasonic electrosurgical devices market size is expected to reach USD 5.45 billion by 2028 and is expected to expand at a CAGR of 5.04% from 2021 to 2028.
  • Furthermore, the increasing incidence of cancer across the globe is predicted to boost the demand for ultrasonic electrosurgical devices.
  • Several manufacturers are focusing on developing technologically advanced ultrasonic electrosurgical devices to maintain a strong market presence.
  • Ultrasonic Electrosurgical Devices Market Variables, Trends & Scope

BioMark to Collaborate with Astrazeneca, Pfizer Canada and The IUCPQ Foundation in a $3.5m Project to Improve Early Detection of Lung Cancer

Patient, MEI, Lung, CEO, BUX, Cancer, Technology, Biomarker, Lung cancer, Disease, General manager, Pfizer, Mutation, AstraZeneca, Hospital, Institut universitaire en santé mentale de Montréal, Diagnosis, Partnership, Fluidigm, CSE, Metabolomics, Survival, Research, Genetics, Investor, Risk, OTC Markets Group, Population, Medical director, Artificial intelligence, Efficiency, FSE, LinkedIn, Evaluation, Medical imaging, Pharmaceutical industry
Tuesday, November 30, 2021 - 1:30pm

Yohan Boss at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Qubec-Universit Laval - IUCPQ-UL).

Key Points: 
  • Yohan Boss at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Qubec-Universit Laval - IUCPQ-UL).
  • The new screening tools will be combining radiomics, genetics and metabolomics biomarkers who will be integrated using artificial intelligence.
  • "When detected early, lung cancer patients have more treatment options and a far greater chance of survival.
  • BioMark is developing proprietary, non-invasive, and accurate liquid biopsy-based cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early and cost-effectively.

Nektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting

NSCLC, Oncology, MD Anderson Cancer Center, Assistant professor, Internal medicine, Melanoma, School, Gayle, NKTR, Risk, Nektar, Norris Cotton Cancer Center, Immunotherapy, Division, Congress, Department, Nektar Therapeutics, Head, Tumor microenvironment, University, LSU, Pembrolizumab, Research, American Board of Commissioners for Foreign Missions, Hematology, PROPEL, Failure, Medical school, Louisiana State University, José Felipe Flores, Forward-looking statement, Large-cell lung carcinoma, Lymphocyte, Virology, NASDAQ, ASH, Society, European Society for Medical Oncology, Abstract, Therapy, Ochsner Medical Center, Safety, American Board of Internal Medicine, Lung cancer, Financial toxicity, SAN, Patent, Webcast, Lithium, Pharmaceutical industry
Tuesday, November 30, 2021 - 1:00pm

In addition, two clinical data presentations for NKTR-255 in patients with relapsed/refractory hematologic malignancies will be presented during the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia from December 11 to December 14, 2021.

Key Points: 
  • In addition, two clinical data presentations for NKTR-255 in patients with relapsed/refractory hematologic malignancies will be presented during the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia from December 11 to December 14, 2021.
  • ePoster will be on display on the ESMO-IO 2021 virtual meeting platform on Monday, December 6, 2021, at 12:00 pm GMT (7:00 a.m.
  • ePoster will be on display on the ASH 2021 virtual meeting platform on Sunday, December 12, 2021, at 6:00 a.m.
  • The event will follow the publication of the NKTR-214 (BEMPEG) PROPEL poster (Abstract #140P) on Monday, December 6, 2021.

OncoHost Welcomes UC Davis Professor, David Gandara, M.D., to Scientific Advisory Board

Patient, CEO, Biomarker, Lung cancer, International Association, Cancer, Precision medicine, University, Lung, Journal of Thoracic Oncology, Addario Lung Cancer Medical Institute, Machine learning, Research, Bonnie J. Addario Lung Cancer Foundation, Society, Prophet, Medicine, BOD, American Society of Clinical Oncology, CMO, ASCO, International Society, Pharmaceutical industry, Medical imaging
Tuesday, November 30, 2021 - 1:00pm

"We are thrilled to have Prof. Gandara, an award-winning researcher and physician, join the OncoHost team.

Key Points: 
  • "We are thrilled to have Prof. Gandara, an award-winning researcher and physician, join the OncoHost team.
  • "His clinical and scientific impact in the field of developing predictive biomarkers for therapeutic efficacy will be invaluable to OncoHost's approach, and we look forward to growing together."
  • "I am delighted to join OncoHost's scientific advisory boardat such an exciting time in the company's development, including the upcoming launch of its host response profiling platform, PROphet," said Prof. Gandara.
  • OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy.

Jazz Pharmaceuticals Announces Commercial Availability in Canada of Zepzelca™ (lurbinectedin), the First New Treatment for Stage III or Metastatic Small Cell Lung Cancer in More Than a Decade

People, Commission, Cell, Risk, Company, Diagnosis, Amp, Hope, McMaster University, Lung cancer, RNA interference, CNS, Time, Government of Canada, Gene silencing, Cancer, MSE, SCLC, Research, Squamous cell carcinoma, Patient, PharmaMar, Failure, Statistics, News, Daily, Health Canada, Jazz Pharmaceuticals, Lung, Twitter, Adult, NASDAQ, Tobacco, Toxicity, Growth, Tissue, Small-cell carcinoma, COVID-19, Treatment of lung cancer, Juravinski Cancer Centre, Science, Disease, Pharmaceutical industry, Uranium, Health insurance
Tuesday, November 30, 2021 - 12:45pm

says Paul Petrelli,general manager, Jazz Pharmaceuticals Canada Inc."We areproudto introduce this meaningful new treatment to patients in Canada."

Key Points: 
  • says Paul Petrelli,general manager, Jazz Pharmaceuticals Canada Inc."We areproudto introduce this meaningful new treatment to patients in Canada."
  • "Patients with small cell lung cancer in the second line and their families have been on the sidelines for far too long.
  • The availability of Zepzelca in Canada is a great new option," says Shem Singh, executive director,Lung Cancer Canada.
  • Small cell lung cancer is sometimes, but not often, called oat cell cancer because the small, oval-shaped cells look like oat grains under a microscope.

LUNGevity Foundation Awards Inaugural Health Equity for Communities Research Awards

Research, Health equity, Patient, Policy, Senior, Caregiver, Cancer, Prostate, Conference, Lung cancer, Smoking, Communications Research Centre Canada, General manager, Population, CBPR, Partnership, HCPS, Public, Human, Bristol Myers Squibb, Community-based participatory research, Breast, Doctor of Philosophy, Education, Milken Institute School of Public Health, Program, Smoker, Latinx, BUT, Survival, Incidence, Helpline, Community health, Public policy, Tobacco, International Institute for Population Sciences, Diversity, Survivor, Multimedia, Department, Strathcona County, Quality of life, Birth control, Medical imaging, Medical device, Pharmaceutical industry
Tuesday, November 30, 2021 - 12:10pm

LUNGevity's Health Equity for Communities Research Award supports young researchers interested in lung cancer CBPR as a way to establish quality outcomes and health equity in high-risk populations.

Key Points: 
  • LUNGevity's Health Equity for Communities Research Award supports young researchers interested in lung cancer CBPR as a way to establish quality outcomes and health equity in high-risk populations.
  • This year, LUNGevity is supporting twoHealth Equity for Communities Research Awards.Each award is for a maximum of $250,000 for 2 years.
  • Experts from LUNGevity's Health Equity Council, chaired by Chief Health Equity and Diversity Officer Jeanne Regnante, guided the selection of the awardees.
  • "We are pleased to support the 2021 inaugural Health Equity in Communities research awards.

MAP Kinase Kinase 1 Inhibitors Pipeline Research Report 2021 - ResearchAndMarkets.com

Health, Biotechnology, Royal commission, Patient, RAS, News, Discovery, Pancreatic cancer, Ovarian cancer, Cancer, Protein, Mitogen-activated protein kinase, Lung cancer, MEK, MAPK, MEK2, EGFR, LGG, Clinical trial, RAF, Food, Disease, Therapy, NF1, Melanoma, Endometrial cancer, Colorectal cancer, Orphan drug, Fast Track, MAP, Selumetinib, III, FDA, European Commission, MEK1, Inhibitor, II, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Growth, Fertilizer, Pharmaceutical industry
Tuesday, November 30, 2021 - 10:06am

The "MAP Kinase Kinase 1 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "MAP Kinase Kinase 1 Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "MAP kinase kinase 1 inhibitors - Pipeline Insight, 2021" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in MAP kinase kinase 1 inhibitors pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence MAP kinase kinase 1 inhibitors R&D.
  • The therapies under development are focused on novel approaches for MAP kinase kinase 1 inhibitors.

DGAP-News: Eckert & Ziegler Partners with University Health Network and CanProbe to Advance PENTIXAFOR Imaging Diagnostic Tool for Wider Application

Patient, CEO, Toronto Rehabilitation Institute, UHN, University, European Medicines Agency, Radiopharmaceutical, Lymphoma, Lung cancer, The Michener Institute, Toronto Western Hospital, Diagnosis, News, Center, Partnership, Cancer, CXCR4, DGAP, Cardiology, Education, TecDAX, Deutsch, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Physician, University Health Network, Commercialization, Research, Health, EMA, Arthritis, ISIN, PET, Neuroscience, Transplant, Reinvigorating Antibiotics and Diagnostic Innovation (READI) Act, Infection, Oncology, Nuclear medicine, Security (finance), Pharmaceutical industry, Medical imaging
Tuesday, November 30, 2021 - 10:03am

The partnership involves clinical research to further advance PentixaPharm's Ga-68 radiodiagnostic tracer PENTIXAFOR in its detection of different tumour entities and other diseases.

Key Points: 
  • The partnership involves clinical research to further advance PentixaPharm's Ga-68 radiodiagnostic tracer PENTIXAFOR in its detection of different tumour entities and other diseases.
  • Eckert & Ziegler (ISIN DE0005659700, TecDAX) and its subsidiary, PentixaPharm GmbH, are working with CanProbe and UHN to provide PENTIXAFOR to patients in Toronto.
  • The intent is to provide further support toward the approval of PENTIXAFOR as a diagnostic agent for a portfolio of different indications.
  • "We are delighted to see this partnership emerging between PentixaPharm, CanProbe, and UHN", adds Luke Brzozowski, Senior Director, Techna and Diagnostics Innovation, University Health Network.

On Target Laboratories Announces FDA Approval of CYTALUX™ (pafolacianine) injection for Identification of Ovarian Cancer During Surgery

Patient, Ovarian cancer, Regulation of tobacco by the U.S. Food and Drug Administration, Folate, Cancer, Skin, Nausea, Indigestion, Technology, Lung cancer, Company, Perelman School of Medicine at the University of Pennsylvania, Surgeon, Palpation, Woman, Drug discovery, Priority review, NRG, Target, Doctor of Philosophy, Allergy, Obstetrics, University, Abdominal pain, Pregnancy, Cytoreductive surgery, Gynecologic Oncology (journal), Adult, Gynaecology, Lymph, Fast Track, Laboratory, Vomiting, Miscarriage, FDA, Purdue University College of Pharmacy, Nursing, and Health Sciences, Uncertainty, Associate, Multimedia, Flushing, Pain scale, Center, Itch, Birth, Food, Pharmaceutical industry, Birth control, Dairy product, Medical imaging
Monday, November 29, 2021 - 4:27pm

CYTALUX is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal.

Key Points: 
  • CYTALUX is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively, enabling the detection of more cancer for removal.
  • CYTALUX serves as an adjunctive tool for surgeons to identify additional malignant ovarian cancer lesions that may have been missed by standard visual inspection and palpation, increasing the detection of more cancer during surgery.
  • "We are excited about the potential impact CYTALUX can have for patients in their fight against ovarian cancer.
  • CYTALUX, the Company's first product, received FDA approval for ovarian cancer in November 2021 and is being studied in the Phase 3 ELUCIDATE Trial for lung cancer in the US.

Body Vision Medical Celebrates 1,000th Patient to Benefit from AI-Driven Lung Cancer Diagnostics Imaging

Patient, Tomography, Adoption, CEO, Technology, CE, Lung cancer, Partnership, Diagnosis, Pulmonology, Physician, Biopsy, 3D, Survival, Fluoroscopy, Artificial intelligence, Vision, CT, Intelligence, Medical imaging
Monday, November 29, 2021 - 1:12pm

NEW YORK, Nov. 29, 2021 /PRNewswire/ -- Body Vision Medical , the pioneer in real-time artificial intelligence imaging for lung cancer diagnostics, announced that 1,000 patients have benefited fromits LungVisionsystem.Body Visionhas FDA and CE approvals andstarted selling commercially earlier this year.

Key Points: 
  • NEW YORK, Nov. 29, 2021 /PRNewswire/ -- Body Vision Medical , the pioneer in real-time artificial intelligence imaging for lung cancer diagnostics, announced that 1,000 patients have benefited fromits LungVisionsystem.Body Visionhas FDA and CE approvals andstarted selling commercially earlier this year.
  • We wouldn't have accomplished this milestone without our continued partnership withpulmonologists whounderstand that real-time imaging and visualconfirmation oftheir diagnostictool inside the lesion are keys to successfully acquiring diagnostic tissueduring lung biopsy," said Dorian Averbuch, CEO & Founder of Body Vision Medical.
  • Body Vision's mission is to make real-time imaging during diagnostic bronchoscopy an option for every lung patient.
  • Body Vision Medical is a medical device company specializing in artificial intelligence, real-time tomographic imaging, augmented fluoroscopy, and visual tool-in-lesion confirmation during diagnostic bronchoscopy.